This session will be available to the first 200 in-person registrants and all virtual registrants during the time of the session and on-demand for all registrants until May 1, 2026.
Complimentary boxed lunches will be provided by ARRS for up to 200 in-person registrants attending this session in San Diego. Seating is limited to 200. Arrive early to secure your seat.
POSLUMA ® (flotufolastat F 18) injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. This program will include the mechanism of action and normal distribution of POSLUMA and review the image interpretation criteria including the pitfalls and clinical case studies.
This presentation is sponsored by Blue Earth Diagnostics, Inc. and will not offer CME credit.